JASPER THERAPEUTICS, INC. Restricted Stock or Unit Expense
JASPER THERAPEUTICS, INC. (JSPR) reported Restricted Stock or Unit Expense of $31.00 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-08.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RestrictedStockExpense · last filed 2023-03-08
- JASPER THERAPEUTICS, INC. restricted stock or unit expense for fiscal 2021 was $31.00M.
| Period end | Restricted Stock or Unit Expense 12 month | Restricted Stock or Unit Expense 12 month as first filed |
|---|---|---|
| 2021-12-31 | $31.00M 10-K · filed 2023-03-08 | $100.00K 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |